---
schema_version: "secwatch.filing_event.v1"
accession: "0001651308-23-000152"
form_type: "8-K"
ticker: "ONC"
cik: "0001651308"
company_name: "BeOne Medicines Ltd."
filed_at: "2023-10-20T23:59:59+00:00"
generated_at: "2026-06-09T18:38:42.897927+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# BeiGene's BRUKINSA receives positive NICE recommendation for CLL in UK

## Summary
- NICE final draft guidance recommends BRUKINSA for untreated CLL with 17p deletion or TP53 mutation, or when FCR/BR unsuitable, and for relapsed or refractory CLL.
- NICE found zanubrutinib cost-effective vs other BTK inhibitors, with lower incremental costs and more QALYs.
- Follows NICE's July 2022 recommendation for Waldenstrom's macroglobulinemia and Scottish Medicines Consortium approval on Oct 9, 2023.
- BRUKINSA approved in over 65 countries; global development program includes 5,000+ subjects in 29 countries.

## SEC filing metadata
- accession: 0001651308-23-000152
- form_type: 8-K
- ticker: ONC
- cik: 0001651308
- company_name: BeOne Medicines Ltd.
- filed_at: 2023-10-20T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1651308/000165130823000152/0001651308-23-000152-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1651308/000165130823000152/bgne-20231020.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001651308-23-000152
- JSON: https://secwatch.observer/filing/0001651308-23-000152.json
- Plain text: https://secwatch.observer/filing/0001651308-23-000152.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.